A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-10

Study Completion Date

2019-08-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

NCT01532635

Hematologic Malignancy Leukemia Acute Lymphoblastic Leukemia +9 more

TERMINATED PHASE2

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

NCT01349101

Hematological Malignancies

COMPLETED PHASE2

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

NCT00429143

Hematologic Malignancies

COMPLETED PHASE1/PHASE2

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

NCT00611351

Graft Versus Host Disease Leukemia Lymphoma +4 more

COMPLETED PHASE2

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

NCT01341301

Hematologic Malignancy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research protocol has been developed for patients undergoing matched-sibling hematopoietic stem cell transplant (HSCT). The patients who are treated according to this 2 step allogeneic HSCT protocol will receive cyclophosphamide to induce in-vivo tolerization of both autologous and allogeneic lymphocytes, followed by an allogeneic CD34-selected HSCT. The primary research questions relate to immune reconstitution, incidence of GVHD, and relapse in patients who receive lymphocyte treatment of this type in allogeneic HSCT and how it impacts overall survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematological Malignancies Leukemia Lymphoma Multiple Myeloma Hodgkin's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allogeneic Transplantation

Matched Sibling Allogeneic Transplantation

Group Type EXPERIMENTAL

Matched Sibling Allogeneic Transplantation

Intervention Type DEVICE

Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Matched Sibling Allogeneic Transplantation

Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CliniMACS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. Patients will be considered high-risk if they have any of the following:

1. Age \> 50 years
2. ECOG Performance status of \<2
3. Acute leukemia: requiring more than one chemotherapy regimen to obtain 1st CR; second or greater CR, 1st relapse; any ph+ ALL
4. CML 2nd chronic phase, accelerated phase, or blastic phase
5. MDS with IPS of Intermediate 2 or greater
6. Any myeloproliferative disorder
7. Hodgkin lymphoma: relapsed, refractory, or primary induction failure
8. Non-Hodgkin lymphoma: relapsed, refractory, primary treatment failure, or not eligible for an autologous HSCT
9. Other conditions not listed will be assessed as high-risk by the PI
2. Patients must have a related donor who is either HLA-identical or a one antigen mismatch at the HLA- A; B; C; and DR loci.
3. Patients must adequate organ function:

1. LVEF of \>45%
2. DLCO (adjusted for hemoglobin) \>45% of predicted
3. Adequate liver function as defined by a serum bilirubin \<1.8, AST or ALT \< 2.5X upper limit of normal
4. Creatinine clearance of \> 60 ml/min
4. Patients must be willing to use contraception if they have childbearing potential
5. Able to give informed consent

Exclusion Criteria

1. ECOG performance status of 3 or 4.
2. HIV positive
3. Active involvement of the central nervous system with malignancy
4. Psychiatric disorder that would preclude patients from signing an informed consent
5. Pregnancy
6. Patients with life expectancy of \< 6 months for reasons other than their underlying hematologic/oncologic disorder.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No